Can Lyell Immunopharma (LYEL) Stock Reach $38?

Key Takeaways

• The central target of $38 is the arithmetic mean of seven individual analyst price targets reviewed for LYEL, rounded from roughly $37.70.
• Analyst targets span an unusually wide range from $12 to $49, reflecting deep disagreement about the company's clinical-stage pipeline.
• With shares near $8.80, reaching $38 would require upside of roughly 330% — a very large move by any standard.
• Bullish analysts emphasize ronde-cel in large B-cell lymphoma and LYL273 in colorectal cancer as potential value drivers.
• The principal risks are clinical and regulatory execution, cash burn, and the skepticism reflected in Bank of America's $12 Sell rating.

Analyst Price Targets and Consensus View

Lyell Immunopharma, Inc. (LYEL) is a clinical-stage CAR T-cell (chimeric antigen receptor T-cell) therapy developer. Across seven individual, identifiable analyst targets, the arithmetic mean is approximately $37.70, which rounds to a central target of $38. This is broadly consistent with the ~$38 average reported by data providers such as S&P Global.

The range is extraordinarily wide. On the cautious end, Bank of America Securities reiterates a Sell rating with a $12 target (August 2026). On the bullish end, Robert W. Baird initiated coverage at $49 (April 2026). In between sit H.C. Wainwright at $45 (September 2026), B. Riley Securities at $44, Needham at $44, Stifel at $36, and Citizens at $34. H.C. Wainwright upgraded the shares from Neutral to Buy in December 2025, roughly doubling its target to $45 after colorectal cancer data and a key opinion leader call.

The wide dispersion is not random. Bullish analysts argue the dual-targeting ronde-cel candidate is emerging as a "durability leader" in the CD19/CD20 CAR-T field, while bears question whether early data can convert into durable commercial franchises given safety and later-line positioning concerns. The mean should be read as a blended view, not a guarantee.

Current Market Position and Path Toward the Target

At a latest verified price near $8.80, with a 52-week range of roughly $7.20 to $45.00, the shares sit near their low after a steep 2026 decline. Reaching $38 implies roughly 330% upside, which is a very large move. Notably, the stock traded above $40 in late 2025, so the target is not a figure the market has never seen — but the shares have since retraced sharply.

The path toward $38 would almost certainly require positive pivotal clinical data. Ronde-cel is in the registrational PiNACLE trial in third-line-plus large B-cell lymphoma, with a Phase 3 head-to-head study (PiNACLE-H2H) planned in the second-line setting. LYL273, a GCC-targeted CAR T for metastatic colorectal cancer, reported that gastrointestinal prophylaxis reduced Grade 2 or higher diarrhea/colitis from 55% to 10%. An end-of-Phase 1 meeting is expected in 2027. Because revenue is negligible (under $100,000 trailing twelve months), any re-rating hinges on clinical catalysts rather than earnings.

What Could Support a Move Toward the Target

• Clinical differentiation: Ronde-cel's dual CD19/CD20 targeting and the LYL273 safety data underpin the bullish case for best-in-class durability.
• Analyst conviction: Five of the seven firms carry Buy or Outperform ratings with targets from $34 to $49.
• Cash position: Roughly $204 million in cash provides runway into the third quarter of 2027, covering key catalysts.
• Large addressable markets: Relapsed/refractory large B-cell lymphoma and late-line colorectal cancer represent substantial unmet need.

What Could Prevent the Target From Being Reached

• Clinical and regulatory risk: Pivotal trials can fail or be delayed; regulators may require larger, longer studies.
• Cash burn: The company posted a net loss near $248 million over the trailing twelve months.
• Bearish skepticism: Bank of America's $12 Sell target reflects doubts that early signals translate into a commercial franchise.
• Dilution and sentiment: A micro-cap biotech with minimal revenue remains vulnerable to financing overhangs and sector-wide rotation away from speculative names.

Technical Levels and Market Structure

The shares are trading in a pronounced downtrend, well below their 200-day moving average after losing more than half their value over the past six months. Immediate support sits in the $7.20–$8.21 zone, the 52-week low. On the upside, the stock must first reclaim the $10–$13 area, where it consolidated in September 2026, before any test of the $45 high becomes relevant. These levels are distant from the $38 target, underscoring the magnitude of the move required.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms apply different methodologies and time frames. Key items to watch include ronde-cel data from the PiNACLE program, additional LYL273 colorectal cancer readouts, the end-of-Phase 1 meeting expected in 2027, quarterly cash-burn updates, and any analyst target revisions. Because the company is pre-revenue, clinical and regulatory milestones matter far more than quarterly earnings results.

AI Daily Buy/Sell Signals

AI Daily Buy/Sell Signals from Tickeron use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from shifting market conditions, technical behavior, and AI-driven analysis. For a volatile, catalyst-driven name like LYEL, such tools can help traders discover opportunities, monitor positions, and spot changing trends more efficiently than manual chart review. Traders looking to complement their own research on the stock's trend structure may find the signals a useful, time-saving addition to their workflow.

Final Assessment

The question of whether LYEL can reach $38 is ultimately a question about clinical execution rather than near-term fundamentals. The central target of $38 — the mean of seven analyst targets spanning $12 to $49 — sits roughly 330% above the current price, a very large gap that reflects both the stock's 2026 collapse and the asymmetric, binary nature of a pre-revenue CAR-T developer. Supporters point to ronde-cel's durability profile and the improved LYL273 safety data; skeptics, led by Bank of America's $12 Sell, warn that commercial success is far from assured. Investors should watch the pivotal lymphoma data, the colorectal program's regulatory path, and cash runway, while treating the wide analyst range as evidence of genuine uncertainty rather than a reliable roadmap.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations